DBV Technologies upgraded by Societe Generale
$DBVT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Societe Generale upgraded DBV Technologies from Hold to Buy
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/15/2025 | $42.00 | Overweight | Cantor Fitzgerald |
| 12/3/2025 | $35.00 | Buy | Guggenheim |
| 5/29/2025 | $7.25 | Sell | Goldman |
| 1/4/2023 | Hold → Buy | Societe Generale | |
| 12/16/2022 | Neutral → Sell | Goldman | |
| 5/10/2022 | $6.00 → $1.50 | Buy → Neutral | Goldman |
| 12/21/2021 | $8.00 → $5.00 | Market Outperform | JMP Securities |
| 12/21/2021 | $14.00 → $10.00 | Buy | HC Wainwright & Co. |
4 - DBV Technologies S.A. (0001613780) (Issuer)
4 - DBV Technologies S.A. (0001613780) (Issuer)
Châtillon, France, July 17, 2026 DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales DBV Technologies (TRQX:DBVp) (the "Company"), a late-stage biopharmaceutical company, today announced that it has filed a new automatically effective shelf registration statement on Form S-3ASR (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC"), which includes a base prospectus and a sales agreement prospectus supplement refreshing the Company’s previously established at-the-market offering program (the "ATM Program") by filing a prospectus supplement for sales of up to $150 million of American Depositary Shares ("ADS"). The ATM Prog
Châtillon, France, July 16, 2026 DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company (the "Company"), today announced the filing, for the semester ended June 30, 2026, of its Half-Year Report with the French market authority, "Autorité des Marchés Financiers" ("AMF"). The 2026 Half-Year Report can be consulted or downloaded from the Company’s website (www.dbv-technologies.com) in the section Investors/Financial Information, and on the AMF website (www.amf-france.org), in French only. About DBV Technologies DBV Technologies is a late-stage biopharmaceut
Châtillon, France, July 16, 2026 DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update Continued productive engagement with the FDA in support of the BLA for the VIASKIN® Peanut Patch in children aged 4 through 7 years, with submission of the BLA anticipated in the third quarter of 2026Reported cash and cash equivalents of $174.9 million as of June 30, 2026, funding into third quarter of 2027 DBV will host a conference call today, July 16, at 5:00pm ET DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company, today reported financial results for the Second Quarter and Half-Year of 2026. The quarterly and Half-Year financial statements
Cantor Fitzgerald initiated coverage of DBV Technologies with a rating of Overweight and set a new price target of $42.00
Guggenheim initiated coverage of DBV Technologies with a rating of Buy and set a new price target of $35.00
Goldman resumed coverage of DBV Technologies with a rating of Sell and set a new price target of $7.25
SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)
SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)
SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)
8-K - DBV Technologies S.A. (0001613780) (Filer)
10-Q - DBV Technologies S.A. (0001613780) (Filer)
8-K - DBV Technologies S.A. (0001613780) (Filer)
3 - DBV Technologies S.A. (0001613780) (Issuer)
4 - DBV Technologies S.A. (0001613780) (Issuer)
4 - DBV Technologies S.A. (0001613780) (Issuer)
Châtillon, France, July 16, 2026 DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update Continued productive engagement with the FDA in support of the BLA for the VIASKIN® Peanut Patch in children aged 4 through 7 years, with submission of the BLA anticipated in the third quarter of 2026Reported cash and cash equivalents of $174.9 million as of June 30, 2026, funding into third quarter of 2027 DBV will host a conference call today, July 16, at 5:00pm ET DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company, today reported financial results for the Second Quarter and Half-Year of 2026. The quarterly and Half-Year financial statements
Châtillon, France, July 14, 2026 DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026 Company to host investor conference call and webcast at 5:00 p.m. ET DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Thursday, July 16th, at 5:00 p.m. ET to review its second quarter 2026 financial results and provide a business update. Interested participants may access this call via the teleconferencing numbers below and by asking to join the DBV Technologies Second Quarter 2026 Results call: United States: +1-877-344-8082 International: +1-2
Châtillon, France, June 29, 2026 DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing DBV has been engaged in extensive discussions with the FDA in preparation of its BLA for the VIASKIN® Peanut Patch in children aged four through seven yearsThe objective of the detailed, iterative engagement was to ensure a complete, efficient, and timely FDA review of the BLA, once submittedThe Agency has not requested additional dataDBV will take additional time to incorporate the FDA feedback and anticipates submitting the BLA in the third quarter of 2026D
Châtillon, France, March 24, 2026 DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review Changes went into effect on Monday, March 23, 2026 DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company, today announced that following the annual review of the Euronext Paris indices on March 12, 2026, the Scientific Council of the Indices has admitted DBV to the CAC Mid 60 and SBF 120 Indices. The changes went into effect on Monday, March 23, 2026. "We are proud to be admitted into the CAC Mid 60 and SBF 120 Indices, which reflect the financial markets' recognition of our continued progress," stated Daniel Tassé, Chief Executive Officer of D
Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr. Trapp will report directly to Daniel Tasse, Chief Executive Officer, as a member of the executive team and will lead all aspects of global commercial strategy and execution for the Viaskin® Peanut patch. DBV expects to submit a Biologics License Application (BLA) submission for children 4-7 years-old living with peanut allergy in the first half of 2026, followed by an anticipated BLA su
Châtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (TRQX:DBVp), (the "Company" or "DBV"), a clinical-stage biopharmaceutical company, today announced the provisional appointment of a new independent director, Dr. Philina Lee, to its Board of Directors (the "Board"), effective October 30, 2025. Dr. Lee is appointed in replacement of Daniel Soland, subject to the ratification by the Company's shareholders at the next annual meeting of shareholders. Dr. Lee will also serve as a member of the Compensation Committee of the Board. With this addition, the Company's Board comprises ten directors. "We are pleased